Merck Announces Increased Quarterly Dividend
November 22 2016 - 1:22PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced that the Board of Directors has increased
the company’s quarterly dividend to $0.47 per outstanding share of
the company’s common stock, up $0.01 from $0.46 per outstanding
share paid last quarter. Payment will be made on Jan. 9, 2017, to
stockholders of record at the close of business on Dec. 15,
2016.
“We are making strides toward our overarching goal of bringing
forward medicines and vaccines that create value for society and
shareholders alike,” said Kenneth C. Frazier, chairman and chief
executive officer, Merck. “The dividend increase reflects our
confidence in our innovation strategy and our commitment to
returning meaningful value to our shareholders.”
Merck last announced a dividend increase in November 2015, when
the Board raised the dividend from $0.45 to $0.46 per common
share.
About Merck
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161122005940/en/
MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam,
908-740-1986Amy Klug, 908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024